Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Institute of Biomedical Research, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Mil Med Res. 2021 Nov 1;8(1):57. doi: 10.1186/s40779-021-00351-2.
Mitochondria have been shown to play vital roles during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) development. Currently, it is unclear whether mitochondrial DNA (mtDNA) variants, which define mtDNA haplogroups and determine oxidative phosphorylation performance and reactive oxygen species production, are associated with COVID-19 risk.
A population-based case-control study was conducted to compare the distribution of mtDNA variations defining mtDNA haplogroups between healthy controls (n = 615) and COVID-19 patients (n = 536). COVID-19 patients were diagnosed based on molecular diagnostics of the viral genome by qPCR and chest X-ray or computed tomography scanning. The exclusion criteria for the healthy controls were any history of disease in the month preceding the study assessment. MtDNA variants defining mtDNA haplogroups were identified by PCR-RFLPs and HVS-I sequencing and determined based on mtDNA phylogenetic analysis using Mitomap Phylogeny. Student's t-test was used for continuous variables, and Pearson's chi-squared test or Fisher's exact test was used for categorical variables. To assess the independent effect of each mtDNA variant defining mtDNA haplogroups, multivariate logistic regression analyses were performed to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) with adjustments for possible confounding factors of age, sex, smoking and diseases (including cardiopulmonary diseases, diabetes, obesity and hypertension) as determined through clinical and radiographic examinations.
Multivariate logistic regression analyses revealed that the most common investigated mtDNA variations (> 10% in the control population) at C5178a (in NADH dehydrogenase subunit 2 gene, ND2) and A249d (in the displacement loop region, D-loop)/T6392C (in cytochrome c oxidase I gene, CO1)/G10310A (in ND3) were associated with a reduced risk of severe COVID-19 (OR = 0.590, 95% CI 0.428-0.814, P = 0.001; and OR = 0.654, 95% CI 0.457-0.936, P = 0.020, respectively), while A4833G (ND2), A4715G (ND2), T3394C (ND1) and G5417A (ND2)/C16257a (D-loop)/C16261T (D-loop) were related to an increased risk of severe COVID-19 (OR = 2.336, 95% CI 1.179-4.608, P = 0.015; OR = 2.033, 95% CI 1.242-3.322, P = 0.005; OR = 3.040, 95% CI 1.522-6.061, P = 0.002; and OR = 2.890, 95% CI 1.199-6.993, P = 0.018, respectively).
This is the first study to explore the association of mtDNA variants with individual's risk of developing severe COVID-19. Based on the case-control study, we concluded that the common mtDNA variants at C5178a and A249d/T6392C/G10310A might contribute to an individual's resistance to developing severe COVID-19, whereas A4833G, A4715G, T3394C and G5417A/C16257a/C16261T might increase an individual's risk of developing severe COVID-19.
线粒体在严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染和 2019 年冠状病毒病(COVID-19)发展过程中发挥着至关重要的作用。目前,尚不清楚线粒体 DNA(mtDNA)变体是否与 COVID-19 风险相关,mtDNA 变体定义了 mtDNA 单倍群,并决定了氧化磷酸化性能和活性氧物质的产生。
进行了一项基于人群的病例对照研究,比较了健康对照组(n=615)和 COVID-19 患者(n=536)之间定义 mtDNA 单倍群的 mtDNA 变异的分布。COVID-19 患者的诊断基于通过 qPCR 和胸部 X 射线或计算机断层扫描对病毒基因组进行分子诊断。健康对照组的排除标准是在研究评估前一个月内有任何疾病史。通过 PCR-RFLP 和 HVS-I 测序确定定义 mtDNA 单倍群的 mtDNA 变体,并基于 Mitomap Phylogeny 使用 mtDNA 系统发生分析进行确定。使用学生 t 检验进行连续变量比较,使用 Pearson 卡方检验或 Fisher 确切检验进行分类变量比较。为了评估每个定义 mtDNA 单倍群的 mtDNA 变体的独立影响,进行了多变量逻辑回归分析,以计算调整年龄、性别、吸烟和疾病(包括心肺疾病、糖尿病、肥胖和高血压)等可能混杂因素后的比值比(OR)和 95%置信区间(CI),这些疾病是通过临床和影像学检查确定的。
多变量逻辑回归分析显示,在 C5178a(在 NADH 脱氢酶亚单位 2 基因 ND2 中)和 A249d/T6392C/G10310A(在细胞色素 c 氧化酶 I 基因 CO1 中)/G10310A(在 ND3 中)处最常见的调查 mtDNA 变体(在对照组中超过 10%)与严重 COVID-19 的风险降低相关(OR=0.590,95%CI 0.428-0.814,P=0.001;和 OR=0.654,95%CI 0.457-0.936,P=0.020),而 A4833G(ND2)、A4715G(ND2)、T3394C(ND1)和 G5417A/ C16257a/C16261T(D 环)与严重 COVID-19 的风险增加相关(OR=2.336,95%CI 1.179-4.608,P=0.015;OR=2.033,95%CI 1.242-3.322,P=0.005;OR=3.040,95%CI 1.522-6.061,P=0.002;和 OR=2.890,95%CI 1.199-6.993,P=0.018)。
这是第一项探索 mtDNA 变体与个体发生严重 COVID-19 风险之间关联的研究。基于病例对照研究,我们得出结论,C5178a 和 A249d/T6392C/G10310A 处的常见 mtDNA 变体可能有助于个体抵抗严重 COVID-19 的发生,而 A4833G、A4715G、T3394C 和 G5417A/C16257a/C16261T 可能增加个体发生严重 COVID-19 的风险。